The epidemiology of Alzheimer's disease: Laying the foundation for drug design, conduct, and analysis of clinical trials

Kristine Yaffe; Michael Tocco; Ronald C. Petersen; Catherine Sigler; Leah C. Burns; Christel Cornelius; Ara S. Khachaturian; Michael C. Irizarry; Maria C. Carrillo

doi:10.1016/j.jalz.2011.12.005

The epidemiology of Alzheimer's disease: Laying the foundation for drug design, conduct, and analysis of clinical trials

Kristine Yaffe, Michael Tocco, Ronald C. Petersen, Catherine Sigler, Leah C. Burns, Christel Cornelius, Ara S. Khachaturian, Michael C. Irizarry, Maria C. Carrillo

Research output: Contribution to journal › Article

22 Scopus citations

Abstract

Epidemiological studies increasingly inform Alzheimer's disease (AD) public health impact, prevention strategies, drug targets, therapeutic interventions, and clinical trial design. For this reason, the Alzheimer's Association Research Roundtable convened an international group of AD experts with experience in conducting both observational and clinical trials for a meeting on October 19 and 20, 2010, in Washington, DC, to discuss the role of epidemiologic studies in AD research and therapeutic advances. Topics included wellness markers and risk factors, with a focus on special populations such as those at elevated risk, super agers, and underserved populations. Discussions also highlighted lessons learned from observational studies of aging, cardiovascular disease, and other disease areas, as well as how new technologies have enabled the gathering of data relevant to drug development and clinical trial conduct.

Original language	English (US)
Pages (from-to)	237-242
Number of pages	6
Journal	Alzheimer's and Dementia
Volume	8
Issue number	3
DOIs	https://doi.org/10.1016/j.jalz.2011.12.005
State	Published - May 1 2012

Keywords

Aging
Alzheimer's disease
Dementia
Epidemiology
Mild cognitive impairment

ASJC Scopus subject areas

Epidemiology
Health Policy
Developmental Neuroscience
Clinical Neurology
Geriatrics and Gerontology
Psychiatry and Mental health
Cellular and Molecular Neuroscience

Access to Document

10.1016/j.jalz.2011.12.005

Fingerprint Dive into the research topics of 'The epidemiology of Alzheimer's disease: Laying the foundation for drug design, conduct, and analysis of clinical trials'. Together they form a unique fingerprint.

Cite this

Yaffe, K., Tocco, M., Petersen, R. C., Sigler, C., Burns, L. C., Cornelius, C., Khachaturian, A. S., Irizarry, M. C., & Carrillo, M. C. (2012). The epidemiology of Alzheimer's disease: Laying the foundation for drug design, conduct, and analysis of clinical trials. Alzheimer's and Dementia, 8(3), 237-242. https://doi.org/10.1016/j.jalz.2011.12.005

The epidemiology of Alzheimer's disease : Laying the foundation for drug design, conduct, and analysis of clinical trials. / Yaffe, Kristine; Tocco, Michael; Petersen, Ronald C.; Sigler, Catherine; Burns, Leah C.; Cornelius, Christel; Khachaturian, Ara S.; Irizarry, Michael C.; Carrillo, Maria C.

In: Alzheimer's and Dementia, Vol. 8, No. 3, 01.05.2012, p. 237-242.

Research output: Contribution to journal › Article

Yaffe, Kristine ; Tocco, Michael ; Petersen, Ronald C. ; Sigler, Catherine ; Burns, Leah C. ; Cornelius, Christel ; Khachaturian, Ara S. ; Irizarry, Michael C. ; Carrillo, Maria C. / The epidemiology of Alzheimer's disease : Laying the foundation for drug design, conduct, and analysis of clinical trials. In: Alzheimer's and Dementia. 2012 ; Vol. 8, No. 3. pp. 237-242.

@article{7046208098f64f9fa60e9add92f1195d,

title = "The epidemiology of Alzheimer's disease: Laying the foundation for drug design, conduct, and analysis of clinical trials",

abstract = "Epidemiological studies increasingly inform Alzheimer's disease (AD) public health impact, prevention strategies, drug targets, therapeutic interventions, and clinical trial design. For this reason, the Alzheimer's Association Research Roundtable convened an international group of AD experts with experience in conducting both observational and clinical trials for a meeting on October 19 and 20, 2010, in Washington, DC, to discuss the role of epidemiologic studies in AD research and therapeutic advances. Topics included wellness markers and risk factors, with a focus on special populations such as those at elevated risk, super agers, and underserved populations. Discussions also highlighted lessons learned from observational studies of aging, cardiovascular disease, and other disease areas, as well as how new technologies have enabled the gathering of data relevant to drug development and clinical trial conduct.",

keywords = "Aging, Alzheimer's disease, Dementia, Epidemiology, Mild cognitive impairment",

author = "Kristine Yaffe and Michael Tocco and Petersen, {Ronald C.} and Catherine Sigler and Burns, {Leah C.} and Christel Cornelius and Khachaturian, {Ara S.} and Irizarry, {Michael C.} and Carrillo, {Maria C.}",

year = "2012",

month = may,

day = "1",

doi = "10.1016/j.jalz.2011.12.005",

language = "English (US)",

volume = "8",

pages = "237--242",

journal = "Alzheimer's and Dementia",

issn = "1552-5260",

publisher = "Elsevier Inc.",

number = "3",

}

TY - JOUR

T1 - The epidemiology of Alzheimer's disease

T2 - Laying the foundation for drug design, conduct, and analysis of clinical trials

AU - Yaffe, Kristine

AU - Tocco, Michael

AU - Petersen, Ronald C.

AU - Sigler, Catherine

AU - Burns, Leah C.

AU - Cornelius, Christel

AU - Khachaturian, Ara S.

AU - Irizarry, Michael C.

AU - Carrillo, Maria C.

PY - 2012/5/1

Y1 - 2012/5/1

N2 - Epidemiological studies increasingly inform Alzheimer's disease (AD) public health impact, prevention strategies, drug targets, therapeutic interventions, and clinical trial design. For this reason, the Alzheimer's Association Research Roundtable convened an international group of AD experts with experience in conducting both observational and clinical trials for a meeting on October 19 and 20, 2010, in Washington, DC, to discuss the role of epidemiologic studies in AD research and therapeutic advances. Topics included wellness markers and risk factors, with a focus on special populations such as those at elevated risk, super agers, and underserved populations. Discussions also highlighted lessons learned from observational studies of aging, cardiovascular disease, and other disease areas, as well as how new technologies have enabled the gathering of data relevant to drug development and clinical trial conduct.

AB - Epidemiological studies increasingly inform Alzheimer's disease (AD) public health impact, prevention strategies, drug targets, therapeutic interventions, and clinical trial design. For this reason, the Alzheimer's Association Research Roundtable convened an international group of AD experts with experience in conducting both observational and clinical trials for a meeting on October 19 and 20, 2010, in Washington, DC, to discuss the role of epidemiologic studies in AD research and therapeutic advances. Topics included wellness markers and risk factors, with a focus on special populations such as those at elevated risk, super agers, and underserved populations. Discussions also highlighted lessons learned from observational studies of aging, cardiovascular disease, and other disease areas, as well as how new technologies have enabled the gathering of data relevant to drug development and clinical trial conduct.

KW - Aging

KW - Alzheimer's disease

KW - Dementia

KW - Epidemiology

KW - Mild cognitive impairment

UR - http://www.scopus.com/inward/record.url?scp=84860447272&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84860447272&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2011.12.005

DO - 10.1016/j.jalz.2011.12.005

M3 - Article

C2 - 22546356

AN - SCOPUS:84860447272

VL - 8

SP - 237

EP - 242

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 3

ER -